SARS Spike (408-470, 540-573)
Protein is >90% pure as determined SDS-PAGE.
Description
The E.coli derived recombinant protein contains the Spike (408-470, 540-573 a.a.) protein immunodominant regions fused to 6xHis tag at C-terminal.
Product Specs
Severe acute respiratory syndrome (SARS) is caused by a newly identified Coronavirus. A key surface antigen of this virus is the SARS Associated Coronavirus Spike protein, making it a prime candidate for vaccine development. Immune responses against Coronaviruses are typically regulated by CD8 T cells.
This recombinant protein, derived from E.coli, encompasses the immunodominant regions of the Spike protein (amino acids 408-470 and 540-573) and is fused with a 6xHis tag at the C-terminal end.
The SARS Spike protein solution is provided in a PBS buffer.
The protein is shipped with ice packs to maintain its temperature. Upon receiving, it should be stored at -20 degrees Celsius.
SDS-PAGE analysis indicates that the protein purity is greater than 90%.
Purified by proprietary chromatographic technique.
Immunoreactive with sera of SARS-infected individuals.
Product Science Overview
The SARS-Associated Coronavirus (SARS-CoV) is a member of the coronavirus family, which includes viruses that can cause illnesses ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The spike (S) protein of SARS-CoV plays a crucial role in the virus’s ability to infect host cells. This article delves into the specific regions of the spike protein, particularly the amino acid sequences 408-470 and 540-573, and their significance in recombinant forms.
The spike protein of SARS-CoV is a transmembrane protein that protrudes from the viral surface, giving the virus its characteristic crown-like appearance. It is composed of two subunits:
- S1 subunit: Responsible for binding to the host cell receptor.
- S2 subunit: Facilitates the fusion of the viral and host cell membranes.
The regions 408-470 and 540-573 within the spike protein are part of the S1 subunit, which contains the receptor-binding domain (RBD). The RBD is critical for the virus’s ability to attach to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells, a key step in viral entry and infection .
Recombinant proteins are produced through recombinant DNA technology, which involves inserting the gene encoding the protein of interest into an expression system, such as bacteria or yeast. The recombinant SARS-CoV spike protein, specifically the regions 408-470 and 540-573, is produced to study the protein’s structure, function, and interactions with host cells. These recombinant proteins are essential for developing vaccines, therapeutic antibodies, and diagnostic tools .
The amino acid sequences 408-470 and 540-573 within the spike protein are highly conserved and immunodominant regions. These regions are crucial for the following reasons:
- Antigenicity: These sequences are recognized by the immune system, making them prime targets for vaccine development.
- Neutralizing Antibodies: Antibodies that target these regions can neutralize the virus by blocking its ability to bind to the ACE2 receptor, preventing infection .
- Structural Stability: These regions contribute to the overall stability of the spike protein, which is essential for maintaining its functional conformation .
The recombinant SARS-CoV spike protein, including the 408-470 and 540-573 regions, has several applications:
- Vaccine Development: These regions are used to design vaccines that elicit a strong immune response, providing protection against SARS-CoV infection.
- Therapeutic Antibodies: Monoclonal antibodies targeting these regions are developed as potential treatments for SARS-CoV infections .
- Diagnostic Tools: Recombinant spike proteins are used in diagnostic assays to detect antibodies in individuals who have been exposed to the virus .
